APA (7th ed.) Citation

Radia, D., DeAngelo, D., Deininger, M. W., Reiter, A., Sen, J., Lin, H. M., . . . Gotlib, J. (2021). MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis: Pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies. Clinical lymphoma, myeloma & leukemia, 21, . https://doi.org/10.1016/S2152-2650(21)01843-7

Chicago Style (17th ed.) Citation

Radia, Deepti, Daniel DeAngelo, Michael W. Deininger, Andreas Reiter, Jayita Sen, Hui Min Lin, Sasa Dimitrijevic, and Jason Gotlib. "MPN-395: Efficacy and Safety of ≤200 Mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies." Clinical Lymphoma, Myeloma & Leukemia 21 (2021). https://doi.org/10.1016/S2152-2650(21)01843-7.

MLA (9th ed.) Citation

Radia, Deepti, et al. "MPN-395: Efficacy and Safety of ≤200 Mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies." Clinical Lymphoma, Myeloma & Leukemia, vol. 21, 2021, https://doi.org/10.1016/S2152-2650(21)01843-7.